Purple Biotech LTD. (PPBT) — 6-K Filings

All 6-K filings from Purple Biotech LTD.. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

Purple Biotech Forms Scientific Advisory Board — Apr 23, 2026 Risk: low
Purple Biotech Ltd. announced on April 23, 2026, the establishment of a Scientific Advisory Board (SAB) to bolster the development of its C-series drug candidat
Purple Biotech Partners with Converge Bio for AI Oncology Acceleration — Mar 25, 2026
Purple Biotech Ltd. announced on March 25, 2026, a new AI collaboration with Converge Bio aimed at accelerating the development of their oncology pipeline. This
Purple Biotech Ltd. Holds Shareholder Meeting — Dec 16, 2025 Risk: low
Purple Biotech Ltd. announced the results of its Extraordinary General Meeting of Shareholders held on December 15, 2025. The meeting took place at the Company'
6-K Filing — Dec 11, 2025
Purple Biotech Ltd. Updates Corporate Presentation — Nov 19, 2025 Risk: low
On November 19, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate Presentation November 2025". This filing i
6-K Filing — Nov 14, 2025
Purple Biotech Hits Manufacturing Milestone for IM1240 — Oct 29, 2025 Risk: medium
On October 29, 2025, Purple Biotech Ltd. announced a significant manufacturing milestone for IM1240, a tri-specific antibody developed on their CAPTN-3 platform
Purple Biotech Schedules Shareholder Meeting for December 15 — Oct 28, 2025 Risk: low
Purple Biotech Ltd. announced on October 28, 2025, that an Extraordinary General Meeting of Shareholders will take place on December 15, 2025, at 4:30 p.m. Isra
Purple Biotech Receives Nasdaq Minimum Bid Price Notification — Oct 20, 2025 Risk: medium
On October 20, 2025, Purple Biotech Ltd. announced it received a notification from Nasdaq regarding its minimum bid price. The company is working to regain comp
Purple Biotech Secures $50M ATM Offering — Sep 19, 2025 Risk: medium
On September 19, 2025, Purple Biotech Ltd. entered into an At The Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC. This agreement allo
Purple Biotech Ltd. Updates Corporate Presentation — Sep 16, 2025 Risk: low
On September 15, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate presentation September 2025". This filing
Purple Biotech Gets European Patent Intention for NT219 Combinations — Sep 10, 2025 Risk: medium
On September 10, 2025, Purple Biotech Ltd. announced it received an intention to grant a European patent for its NT219 drug when used in combination with immuno
Purple Biotech Files 6-K with Warrant Forms and Press Release — Sep 5, 2025 Risk: medium
Purple Biotech Ltd. filed a Form 6-K on September 5, 2025, reporting on its activities for the month of September 2025. The filing includes exhibits such as the
Purple Biotech Announces IM1240 Data — Sep 4, 2025 Risk: medium
On September 4, 2025, Purple Biotech Ltd. announced new data supporting the unique design of their tri-specific antibody, IM1240. This announcement was made in
Purple Biotech Adds Novel TROP2 Antibody to CAPTN-3 Portfolio — Sep 3, 2025 Risk: medium
On September 3, 2025, Purple Biotech Ltd. announced the expansion of its CAPTN-3 portfolio with the addition of IM1305, a novel tri-specific antibody. This new
Purple Biotech Reports Q2 2025 Financial Results — Aug 6, 2025 Risk: low
Purple Biotech Ltd. reported its second quarter 2025 financial results on August 6, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot,
Purple Biotech CEO Updates Shareholders on H1 2025 Progress — Jul 23, 2025 Risk: low
On July 23, 2025, Purple Biotech Ltd. issued a press release detailing their progress in the first half of 2025. The CEO's letter to shareholders highlighted si
Purple Biotech Updates Corporate Presentation — Jul 10, 2025 Risk: low
On July 10, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate presentation July 2025". This filing is a Repo
Purple Biotech Highlights CAPTN-3 Platform at EACR 2025 — Jun 23, 2025 Risk: low
On June 23, 2025, Purple Biotech Ltd. announced significant advantages of its novel CAPTN-3 tri-specific antibody platform at the EACR 2025 Annual Conference. T
Purple Biotech Starts Phase 2 Study for NT219 in Head and Neck Cancer — Jun 17, 2025 Risk: medium
On June 17, 2025, Purple Biotech Ltd. announced the initiation of a Phase 2 study for its drug candidate NT219. This study will evaluate NT219 in patients diagn
Purple Biotech Reports Q1 2025 Financial Results — May 21, 2025 Risk: low
Purple Biotech Ltd. reported its first quarter 2025 financial results on May 21, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Is
Purple Biotech Appoints New CFO — May 12, 2025 Risk: low
Purple Biotech Ltd. announced on May 12, 2025, the appointment of Shai Lankry as its new Chief Financial Officer. This appointment is detailed in a press releas
Purple Biotech Ltd. Updates Company Presentation — May 6, 2025 Risk: low
On May 6, 2025, Purple Biotech Ltd. made available an updated Company Presentation on its website. This presentation is attached as Exhibit 99.1 to the 6-K fili
Purple Biotech Reports Final CM24 Pancreatic Cancer Data — Apr 30, 2025 Risk: medium
Purple Biotech Ltd. announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at the AACR 2025 Annual Meeting on April 30, 2025. The stu
Purple Biotech Reports Positive NT219 Data — Apr 28, 2025 Risk: medium
On April 28, 2025, Purple Biotech Ltd. announced positive data from its Phase 1b study of NT219 in combination with nivolumab for patients with metastatic color
Purple Biotech Ltd. Holds Annual Shareholder Meeting — Apr 22, 2025 Risk: low
Purple Biotech Ltd. announced the results of its Annual General Meeting of Shareholders held on April 22, 2025. The meeting took place at the company's offices
Purple Biotech's NT219 Shows Promise Against Brain Metastasis — Apr 16, 2025 Risk: medium
On April 16, 2025, Purple Biotech Ltd. announced the publication of findings in the Neuro Oncology Journal. The study demonstrated the potential of their drug c
Purple Biotech Ltd. Annual Meeting Adjourned — Apr 15, 2025 Risk: medium
Purple Biotech Ltd. held its Annual Meeting of Shareholders on April 15, 2025, which was convened and adjourned without any business being transacted. The compa
Purple Biotech to Speak at Oncology Conference — Apr 1, 2025 Risk: low
Purple Biotech Ltd. announced on April 1, 2025, that it will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference
Purple Biotech to Present at 2025 AACR Meeting — Mar 28, 2025 Risk: low
On March 28, 2025, Purple Biotech Ltd. announced that three of its posters have been accepted for presentation at the 2025 American Association for Cancer Resea
Purple Biotech Ltd. Updates Company Presentation — Mar 18, 2025 Risk: low
On March 18, 2025, Purple Biotech Ltd. made available an updated Company Presentation on its website. This presentation is attached as Exhibit 99.1 to the 6-K f
Purple Biotech Secures New US Patent for NT219 Combination Therapy — Mar 5, 2025 Risk: low
On March 5, 2025, Purple Biotech Ltd. announced it has been granted a new U.S. patent for its NT219 drug when used in combination with EGFR antibody therapy. Th
Purple Biotech Sets April 15 AGM Date — Feb 28, 2025 Risk: low
Purple Biotech Ltd. announced its Annual General Meeting of Shareholders will take place on Tuesday, April 15, 2025, at 4:30 p.m. Israel time. The meeting will
Purple Biotech Advances NT219 to Phase 2 for Head and Neck Cancer — Feb 18, 2025 Risk: medium
On February 18, 2025, Purple Biotech Ltd. announced the advancement of its drug candidate NT219 into a Phase 2 clinical trial for head and neck cancer. This mil
Purple Biotech Partners with Mount Sinai for Antibody Platform — Feb 3, 2025 Risk: medium
On February 3, 2025, Purple Biotech Ltd. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to advance their CAPTN-3 tri-specif
Purple Biotech Ltd. Files 6-K on ATM Agreement — Jan 6, 2025 Risk: low
Purple Biotech Ltd. is filing a Form 6-K for January 2025, reporting on its Open Market Sale Agreement (ATM Agreement) with Jefferies LLC, entered into on June
Purple Biotech Ltd. Updates Company Presentation — Dec 6, 2024 Risk: low
On December 6, 2024, Purple Biotech Ltd. announced it has made available an updated Company Presentation on its website. This presentation is attached as Exhibi
Purple Biotech Closes $2.8M ADS Offering — Dec 5, 2024 Risk: medium
On December 5, 2024, Purple Biotech Ltd. announced the closing of a registered direct offering, successfully raising $2.8 million through the sale of American D
Purple Biotech Files 6-K with Purchase Agreement Details — Dec 4, 2024 Risk: low
Purple Biotech Ltd. filed a Form 6-K on December 4, 2024, reporting a Securities Purchase Agreement and related documents. The filing includes exhibits such as
Purple Biotech Raises $2.8M in Direct Offering — Dec 3, 2024 Risk: medium
On December 3, 2024, Purple Biotech Ltd. announced a registered direct offering to raise $2.8 million through the sale of American Depositary Shares. The compan
Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results — Dec 2, 2024 Risk: medium
On December 2, 2024, Purple Biotech Ltd. announced positive final results from a Phase 2 study of its drug CM24 in patients with second-line pancreatic cancer.
Purple Biotech Reports Q3 2024 Financial Results — Nov 15, 2024 Risk: low
Purple Biotech Ltd. announced its third quarter 2024 financial results on November 15, 2024. The company, formerly known as Kitov Pharma Ltd., is based in Rehov
Purple Biotech Identifies Oncology Biomarker Linked to 79% PFS Reduction — Nov 4, 2024 Risk: medium
On November 4, 2024, Purple Biotech Ltd. announced the identification of a potential new serum biomarker for its lead oncology therapeutic candidate, CM24. This
Purple Biotech Presents CAPTN-3 Data at EORTC-NCI-AACR — Oct 25, 2024 Risk: medium
On October 25, 2024, Purple Biotech Ltd. announced new data for its CAPTN-3 antibody platform, which targets tri-specific T cell and NK cell engagers. This pres
Purple Biotech to Present CAPTN-3 Data at EORTC-NCI-AACR Symposium — Oct 10, 2024 Risk: medium
On October 10, 2024, Purple Biotech Ltd. announced it will present data for its Tri-Specific Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Mole
Purple Biotech Ltd. Updates Company Presentation — Oct 9, 2024 Risk: low
On October 9, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit
Purple Biotech Regains Nasdaq Bid Price Compliance — Oct 2, 2024 Risk: medium
On October 1, 2024, Purple Biotech Ltd. received confirmation from Nasdaq that it had regained compliance with the minimum bid price requirement. The company ha
Purple Biotech Reports Positive Phase 2 Data for Candida — Sep 18, 2024 Risk: medium
On September 18, 2024, Purple Biotech Ltd. announced additional positive interim data from its Phase 2 study of its oncology therapeutic, Candida. The study is
Purple Biotech to Change ADS Ratio — Sep 11, 2024 Risk: medium
Purple Biotech Ltd. announced on September 11, 2024, its intention to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares. The comp
Purple Biotech Ltd. Updates Company Presentation — Aug 19, 2024 Risk: low
On August 19, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX